China News Service Client Beijing, April 10 (Zuo Yukun) With the spread of the New Coronary Pneumonia epidemic around the world, following the Chinese ventilator, the Chinese patent medicine represented by Lianhua Qingwen has become a "hot commodity."
Domestic delivery to foreign countries, foreign fire to domestic
Twenty disposable medical masks, two KN95 masks, two boxes of Lianhua Qingwen capsules, a pack of medical disinfectant wipes, a new coronary pneumonia protection manual ... A few days ago, Bai Yi (a pseudonym), a Chinese student abroad Received the health package from the embassy.
She told reporters that, while envious of many foreign students, she came to ask her what was in her health bag, and they also had to buy some according to it.
What looks most special is the Chinese patent medicine Lianhua Qingwen Capsule. After the outbreak of the overseas epidemic, the Chinese medical expert team once carried Lianhua Qingwen to support Italy and other countries.
Bai Yi said that when some of the Chinese people he joined had uncomfortable symptoms similar to new coronary pneumonia, they would ask who had Lianhua Qingwen in the group.
Health package received by international students. Photo courtesy of interviewees
The reporter inquired about several pharmacies in Beijing, all of which were sold with Lianhuaqingwen. Many shop assistants mentioned that many people recently "come here" to prepare a few boxes for the family.
"We will also introduce to customers that Lianhua Qingwen is a patented Chinese medicine independently developed and produced by our country during the SARS period. Usually there is a flu or something, and it is also useful to eat it in time." A pharmacy clerk told reporters that there were When an old man came in to buy Lianhua Qingwen, he couldn't remember the name of the medicine and asked himself, "Which medicine is Zhong Nanshan saying is useful?"
On March 25, Academician Zhong Nanshan said at the Sino-European Anti-epidemic Exchange Meeting that Lianhua Qingwen had a significant effect on the treatment of new coronary pneumonia. The rehabilitation rate of 284 patients treated with Lianhua Qingwen reached 91.5%.
Zhang Boli, academician of the Chinese Academy of Engineering and president of Tianjin University of Traditional Chinese Medicine, also introduced that the main functions of Lianhua Qingwen are detoxification, lung detoxification, and definite curative effect on patients with mild and common neopneumonia.
Stable domestic sales, hard to find high prices abroad
According to the information disclosed by Lianhua Qingwen's manufacturer Yiling Pharmaceutical, the company has gradually adjusted its production plan according to market demand from March. It has now returned to normal production and Lianhua Qingwen is out of stock in some domestic terminals. Has been relieved.
"Lianhua Qingwen and other enterprises have been producing at full capacity, the inventory is relatively sufficient, and the market supply is guaranteed." Cao Xuejun, deputy director of the Consumer Goods Industry Department of the Ministry of Industry and Information Technology, said at the press conference on April 8 that as of now, Lianhua Qingwen Capsule Day The production capacity has reached 2 million boxes and the inventory is 30 million boxes.
The clerk of the offline pharmacy also said that the supply of Lianhua Qingwen has been relatively stable recently and no notice of price increases has been received. The reporter inquired about online and offline pharmacies and found that the 24 pieces of Lianhua Qingwen Capsules currently on sale are priced between 15-20 yuan per box, and the volume is relatively sufficient.
But on the cross-border e-commerce eBay platform, the price of products of the same specifications has increased several times, the average price is around 70 yuan, and the receipt time will have to wait for half a month or more.
Lianhua Qingwen capsules sold on eBay. Screenshot
Due to its particularity, drugs cannot be bought and sold in other countries at will, and sales in other countries must be registered in accordance with relevant local laws and regulations to obtain marketing authorization.
According to the information disclosed by Yiling Pharmaceutical, except for the mainland China, Hong Kong and Macau regions, Lianhua Qingwen was only registered in 6 countries including Brazil, Indonesia, Canada, Mozambique, Romania, and Thailand to obtain listing approval.
Yiling Pharmaceutical disclosed that the company is actively promoting the overseas registration of Lianhua Qingwen products. Taking the United States as an example, the second-phase clinical research trial carried out by Lianhua Qingwen in the FDA of the United States is still advancing normally, but the third-phase clinical work needs to be carried out after the second-phase clinical end.
Not only can it not be purchased directly, Bai Yi told reporters that under the current epidemic situation, even drugs such as Lianhua Qingwen are difficult to reach abroad if they are sent from the country by individuals. Some overseas Chinese organizations are trying to get through diplomatic channels or logistics from the embassy, but this is not easy.
Regarding Lianhua Qingwen's overseas sales, Lingling Pharmaceutical replied: The company's current sales of Lianhua Qingwen products in registered countries and regions are completed through local agents, and the agents will report to the company at the agent price agreed with the company. payment. The sales price of drugs in the local area is determined by the agent based on the actual local conditions.
Yiling Pharmaceutical's stock price doubled, founder's net worth exceeded 10 billion
On March 30, Yiling Pharmaceutical released the first quarter 2020 performance forecast, saying that the first quarter net profit is expected to be 430 million to 460 million yuan, an increase of 50% to 60% over the previous year. The change in performance was mainly due to the substantial increase in the operating income of Lianhua Qingwen products in the first quarter compared with the same period last year.
Shijiazhuang Yiling Pharmaceuticals stepped up production of Lianhua Qingwen Capsules. Photo courtesy of Hebei Provincial Drug Administration
The blessings of many medical institutions and experts have made Yiling Pharmaceutical's share price hit a new high. From 12.43 yuan / share at the beginning of the year to 24.96 yuan / share at the close of April 9, the rate of increase since 2020 has exceeded 100%.
With the increase in both the share price and performance of Yiling Pharmaceuticals, the net worth of its founder, Wu Yiling, academician of the Chinese Academy of Engineering known as the "A-share richest academician" will also soar. Hurun released the "2020 Hurun Global Rich List" on February 26, 2020. The Wu Yiling family has 11 billion yuan of wealth.
Yiling Pharmaceutical also said that the company will seize the opportunity brought by the further increase in the popularity of Lianhua Qingwen products and do a good job in product promotion and sales under normal conditions. (Finish)